CRISPR Therapeutics (CRSP) shares closed at US$53.77 on Friday, with recent returns mixed, including a 2.5% gain over the past day but a weaker pattern over the month and the past 3 months. See our ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with ...

On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Friday, December 26, according to its daily fund ...

Cathie Wood has seldom shied away from letting everyone know where she believes the next wave of market-changing businesses ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (NASDAQ: CRSP) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 ...

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...